Tiziana Life Sciences (Tiziana Life Sciences) Growth Rank : 0 (As of May. 25, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Tiziana Life Sciences Growth Rank?

Tiziana Life Sciences has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Tiziana Life Sciences Growth Rank Related Terms

Thank you for viewing the detailed overview of Tiziana Life Sciences's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Tiziana Life Sciences (Tiziana Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tiziana Life Sciences Ltd (NAS:TLSA) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

0RP:Germany

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM 11

Website

https://www.tizianalifesciences.com

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.